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Introduction: Polyadenylation is the process in which the pre-mRNA is cleaved at the
poly(A) site and a poly(A) tail is added – a process necessary for normal mRNA formation.
Genes with multiple poly(A) sites can undergo alternative polyadenylation (APA), producing
distinct mRNA isoforms with different 3′ untranslated regions (3′ UTRs) and in some cases
different coding regions. Two thirds of all human genes undergo APA. The efficiency of
the polyadenylation process regulates gene expression and APA plays an important part
in post-transcriptional regulation, as the 3′ UTR contains various cis-elements associated
with post-transcriptional regulation, such as target sites for micro-RNAs and RNA-binding
proteins.
Implications of alterations in polyadenylation for endocrine disease: Alterations in
polyadenylation have been found to be causative of neonatal diabetes and IPEX (immune
dysfunction, polyendocrinopathy, enteropathy, X-linked) and to be associated with type I
and II diabetes, pre-eclampsia, fragile X-associated premature ovarian insufficiency, ectopic
Cushing syndrome, and many cancer diseases, including several types of endocrine tumor
diseases.
Perspectives: Recent developments in high-throughput sequencing have made it possible
to characterize polyadenylation genome-wide. Antisense elements inhibiting or enhancing
specific poly(A) site usage can induce desired alterations in polyadenylation, and thus hold
the promise of new therapeutic approaches.
Summary: This review gives a detailed description of alterations in polyadenylation in
endocrine disease, an overview of the current literature on polyadenylation and summarizes
the clinical implications of the current state of research in this field.
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INTRODUCTION
BACKGROUND
Almost all eukaryotic pre-messenger RNAs (pre-mRNAs) and sev-
eral non-coding transcripts have poly(A) sites and are polyadeny-
lated (Shepard et al., 2011; Derti et al., 2012; Lin et al., 2012). Sev-
eral studies have mapped poly(A) sites genome-wide in humans
(Tian et al., 2005; Yan and Marr, 2005; Ozsolak et al., 2010; Fu et al.,
2011; Shepard et al., 2011; Derti et al., 2012; Lin et al., 2012). One of
the latest found that more than two thirds of all genes have multiple
Abbreviations: 3′ UTR, 3′ untranslated region; APA, alternative polyadenylation;
ARE, AU-rich element; Aux-DSE, auxiliary downstream element; CBC, nuclear cap-
binding complex; CF-I and CF-II, cleavage factor I and II; CGRP, calcitonin gene-
related peptide; CIN, chromosome instability; CPSF, cleavage and polyadenylation
specificity factor; CR-APA, coding region-APA; CstF, cleavage stimulation factor;
CTD, C-terminal domain; DSE, downstream sequence element; FMR1, fragile X
mental retardation 1; GRE,GU-rich element; GWAS,genome-wide association stud-
ies; HSF1, heat shock factor 1; IA-2, tyrosine phosphatase; IGF-1, insulin-like growth
factor 1; IPEX, immune dysfunction, polyendocrinopathy, enteropathy, X-linked;
LOH, loss of heterozygosity; MCL, mantle cell lymphoma; miRNA, micro-RNA;
mRNA, messenger RNA; PABPN1, nuclear poly(A)-binding protein; PAP, poly(A)
poly(A) sites and can therefore undergo alternative polyadenyla-
tion (APA), producing distinct mRNA isoforms with different 3′
untranslated regions (3′ UTRs) (Derti et al., 2012). Polyadeny-
lation and APA are emerging as important regulators of gene
expression and alterations in polyadenylation have implications
for many diseases (Danckwardt et al., 2008).
This review gives a detailed description of alterations in
polyadenylation in endocrine disease, an overview of the cur-
rent literature on polyadenylation and summarizes the clinical
polymerase; PARP1, poly(ADP-ribose) polymerase 1; PAS, polyadenylation signal;
PDGFRα, platelet-derived growth factor receptor alpha; PI4,5P2, phosphatidyli-
nositol 4,5-bisphosphate; Pol-II, RNA-polymerase II; PTB, polypyrimidine tract
binding protein; RBP, RNA-binding protein; RET, rearranged during transfection;
Ser2, Serine 2; SERT, serotonin transporter; SF3a2, splicing factor 3a subunit 2; sFlt-
1, soluble fms-like tyrosine kinase 1; siRNA, small interfering RNA; SLE, systemic
lupus erythematosus; SNP, single nucleotide polymorphisms; SOCS3, suppressor
of cytokine signaling 3; TB-RBP, testis brain RNA-binding protein; TCF/LEF, T-cell
factor/lymphoid-enhancer factor; TCF7L2, transcription factor 7-like 2; U2AF1 and
U2AF2, U2 auxiliary factor 1 and 2; USE, upstream sequence element; UTR-APA,
untranslated region-APA.
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implications of the current state of research in this field. We
focus on the co-transcriptional, nuclear polyadenylation, as post-
transcriptional and cytoplasmic polyadenylation [alterations to
the already added poly(A) tail] is beyond the scope of this review.
mRNA TRANSCRIPTION AND POLYADENYLATION
Pre-mRNAs are transcribed from protein-coding genes by the
RNA-polymerase II (Pol-II). The nascent pre-mRNA molecule
emerging from the Pol-II goes through the co-transcriptional
processes of 5′ capping, splicing, and polyadenylation before tran-
scription is terminated. Polyadenylation consists of two steps: (1)
Cleavage of the pre-mRNA at a poly(A) site and (2) Addition of an
untemplated 3′ poly(A) tail to the upstream cleavage product. The
specific cleavage position and the efficiency of the process depend
on the interaction between trans-acting polyadenylation factors
and cis-elements present in the pre-mRNAs. All eukaryotic pre-
mRNAs, except some replication-dependent histone pre-mRNAs,
as well as several non-coding transcripts, including micro-RNAs
(miRNAs), have poly(A) sites and are polyadenylated (Shepard
et al., 2011; Derti et al., 2012; Lin et al., 2012). Polyadenylation
is vital for normal mRNA formation, transcription termination
and mRNA export from the nucleus, and affects mRNA stabil-
ity, subcellular localization, and translational efficiency (Sandberg
et al., 2008; Ji and Tian, 2009). As polyadenylation is required
for transcription termination, the efficiency of the polyadeny-
lation process affects gene expression quantitatively (West and
Proudfoot, 2009; Yang et al., 2009; Mapendano et al., 2010).
POST-TRANSCRIPTIONAL REGULATION OF GENE EXPRESSION
Tight regulation of gene expression is essential for cells to per-
form their normal functions and disturbances in gene expression
underlie many diseases. Gene expression can be regulated at any
step, from the pre-transcriptional epigenetic modifications of the
chromatin to the post-translational modifications of the protein
product. A quickly responding part of gene expression regulation is
the post-transcriptional regulation exerted by RNA-binding pro-
teins (RBPs) and miRNAs. RBPs and miRNAs mainly bind target
sequences in the 3′ UTR of mRNAs, thereby controlling mRNA
turnover and translation rate (Keene, 2007; Friedman et al., 2009).
An example of post-transcriptional regulation is seen in the rapid
regulation of insulin level and signaling in response to changes
in glucose level. This regulation is exerted through altered stabil-
ity and translation of insulin mRNA and insulin receptor mRNA,
and helps to maintain glucose homeostasis (reviewed in Lee and
Gorospe, 2010).
ROLE OF ALTERNATIVE POLYADENYLATION IN
POST-TRANSCRIPTIONAL REGULATION
As RBPs and miRNAs mainly target the 3′ UTR, alterations to
the 3′ UTR affect the post-transcriptional regulation. More than
two thirds of all mammalian genes encode alternative mRNA iso-
forms with different 3′UTRs through APA (Derti et al., 2012). APA
therefore plays an important part in the post-transcriptional reg-
ulation, as it determines which isoform of the 3′ UTR is expressed
(Thomsen et al., 2010). This is seen for the insulin receptor mRNA,
from the example above (Levy et al., 1995). Characterization of
polyadenylation is therefore essential for understanding both nor-
mal cell biology as well as disease. Recent advances in sequencing
technologies have made it possible to map poly(A) site usage
genome-wide (Mangone et al., 2010; Ozsolak et al., 2010; Fox-
Walsh et al., 2011; Fu et al., 2011; Jan et al., 2011; Shepard et al.,
2011; Derti et al., 2012; Jenal et al., 2012; Lin et al., 2012; Martin
et al., 2012; Pelechano et al., 2012; Yoon et al., 2012; Hoque et al.,
2013; Wang et al., 2013; Wilkening et al., 2013). These techniques
could be implemented in and improve diagnostics.
POLYADENYLATION
TYPES OF POLYADENYLATION
Constitutive polyadenylation
Genes with a single poly(A) site can only be constitutively
polyadenylated (Figure 1, top), as seen for the INS gene encoding
insulin (Garin et al., 2010). Approximately one third of all human
genes only have one poly(A) site (Derti et al., 2012). For these
genes the efficiency of polyadenylation regulates gene expression
through changes in the transcription termination efficiency (West
and Proudfoot, 2009; Yang et al., 2009; Mapendano et al., 2010).
Weakened polyadenylation can lead to impaired gene expres-
sion and read-through transcription (Higgs et al., 1983), while
enhanced polyadenylation can lead to upregulated gene expression
(Danckwardt et al., 2004).
Alternative polyadenylation
For genes with multiple poly(A) sites, APA can take place (for
review of APA see Neilson and Sandberg, 2010; Di Giammartino
et al., 2011; Proudfoot,2011). Only one of the possible poly(A) sites
in a pre-mRNA is used for polyadenylation per mRNA transcrip-
tion event. APA is typically divided into two categories, UTR-APA
and coding region (CR)-APA.
Untranslated region alternative polyadenylation. Alternative
polyadenylation occurring at alternative poly(A) sites located in
the 3′ UTR of the last exon is called UTR-APA. It results in mRNAs
with the same CR, but with different 3′ UTR length (Figure 1,
middle), as seen for the INSR gene encoding insulin receptor
(Levy et al., 1995). UTR-APA is the most abundant type of APA,
accounting for more than half of the APA events (Yan and Marr,
2005; Shepard et al., 2011). About 70% human genes have mul-
tiple poly(A) sites in their 3′ UTR and undergo UTR-APA (Derti
et al., 2012). The 3′ UTR contains various cis-elements associated
with post-transcriptional gene regulation, such as target sites for
miRNAs and RBPs, as well as AU-rich elements (AREs) and GU-
rich elements (GREs). The 3′ UTR and the factors interacting with
it largely determine mRNA stability, subcellular localization, and
translational efficiency (Sandberg et al., 2008; Ji and Tian, 2009).
It is therefore not surprising, that mutations in the 3′ UTR are
associated with many diseases (reviewed in Chen et al., 2006a,b).
The general length of the 3′ UTRs has been found to be inversely
correlated with cellular proliferation (Sandberg et al., 2008; Elkon
et al., 2012). Individual mRNAs with shorter 3′ UTRs are more sta-
ble (Mayr and Bartel, 2009; Hogg and Goff, 2010; Yepiskoposyan
et al., 2011) and generally produce more protein (Sandberg et al.,
2008; Mayr and Bartel, 2009; Singh et al., 2009). In one study 45%
of the mRNAs with a general 3′ UTR shortening also had signif-
icantly changed expression levels, the majority being upregulated
(de Klerk et al., 2012). This would correlate well with a heightened
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FIGURE 1 |Types of polyadenylation. Green boxes represent
untranslated regions (UTRs), yellow boxes represent shared exons, pink,
and white boxes represent unshared exons and the connecting horizontal
lines represent introns. Adapted from Di Giammartino et al. (2011). Top:
constitutive polyadenylation: gene contains only one poly(A) site and can
therefore not undergo APA. Middle: untranslated region (UTR)-APA: gene
contains multiple poly(A) sites located in the 3′ UTR of the terminal exon.
APA results in mRNAs with different lengths of 3′ UTR, producing the same
protein. Proximal polyadenylation (blue arrow) leads to 3′ UTR shortening,
less post-transcriptional regulation, and enhanced protein translation.
Bottom: coding region (CR)-APA: gene contains additional poly(A) sites
located in the CR of exons and in introns. APA results in mRNAs with
different 3′ UTRs and C-terminal CRs, producing distinct protein isoforms.
Proximal polyadenylation (blue arrow) produces a mRNA with a different
C-terminal CR and 3′ UTR, producing a C-terminally truncated protein
isoform.
mRNA stability for these transcripts. However, no such significant
change in mRNA levels was found in several other studies, where
general changes in 3′ UTR length were also seen (Sandberg et al.,
2008; Fu et al., 2011; Elkon et al., 2012; Morris et al., 2012). The
effects of general changes in 3′ UTR length thus remain unclear.
During normal development, escape of miRNA-mediated regula-
tion by APA is seen (Thomsen et al., 2010; Boutet et al., 2012). In
addition escape of both miRNA- and RBP-mediated regulation by
APA is seen in cancer cells (Boutaud et al., 2003; Sandberg et al.,
2008; Mayr and Bartel, 2009). Genes with UTR-APA have common
parts of the 3′ UTR expressed in all mRNA isoforms and alterna-
tive parts of the 3′ UTR, only expressed in the mRNAs with longer
3′ UTR isoforms. The alternative parts of the 3′ UTR are normally
longer, more AU-rich and contain more cis-elements than the
common parts (Sandberg et al., 2008; Ji and Tian, 2009). Poly(A)
sites preferentially flank cis-elements in the 3′ UTR (Yoon et al.,
2012), as seen for miRNA target sites (Ji and Tian, 2009). Interest-
ingly, more than half of the miRNA targets are found downstream
of the most proximal poly(A) site in the 3′ UTR (Legendre et al.,
2006). The energy expenditure required for synthesizing the longer
3′ UTR isoforms, is used to provide a more refined control of gene
expression, through post-transcriptional regulation, as seen for
StAR mRNA (Zhao et al., 2005). Surprisingly, the 3′UTRs of a large
number of genes are also expressed alone, separately from their
associated protein-coding sequences (Mercer et al., 2011). These
expressed 3′ UTRs are suggested both to have trans-acting roles
and to function as decoys, which can sequester trans-acting factors,
such as miRNAs. UTR-APA in these transcripts would therefore
affect these functions, such as generating multiple isoforms of a
decoying 3′ UTR, each with different miRNA-binding profiles.
For genes undergoing UTR-APA, the efficiency of polyadenylation
contributes to gene expression through the transcription termina-
tion efficiency. In addition to this the choice of different poly(A)
sites through APA plays an important part in post-transcriptional
regulation, as it defines which isoform of the 3′ UTR is expressed
(Thomsen et al., 2010). Dysfunctional polyadenylation can lead to
changes in the APA pattern, altering the 3′ UTR, and to changes in
polyadenylation efficiency, both affecting gene expression.
Coding region alternative polyadenylation. Alternative polyadeny-
lation occurring at alternative poly(A) sites located in introns or
in the CR of exons is called CR-APA. It results in mRNAs with
both different C-terminal CRs and 3′ UTRs (Figure 1, bottom),
as seen for the CALCA gene encoding calcitonin/CGRP (Amara
et al., 1984; Zhou et al., 2007). CR-APA often occurs together with
alternative splicing of the last exon and it is suggested that there is a
dynamic competition between splicing and polyadenylation (Tian
et al., 2007; Evsyukova et al., 2012). About 20% of human genes
have at least one utilized intronic poly(A) site, usually located in
large introns with weak 5′ splice sites (Tian et al., 2007). Thousands
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of dormant intronic poly(A) sites have been characterized, which
are normally suppressed and therefore not utilized (Yao et al.,
2012a). Enhanced usage of intronic poly(A) sites is associated
with proliferation (Elkon et al., 2012) and with a general tran-
scriptional upregulation (Berg et al., 2012). Polyadenylation within
the CR of an exon can convert a Tyr codon to a stop codon and
thereby give rise to a functional mRNA (Yao et al., 2012b). Unlike
mRNAs with acquired premature termination codons, which also
generate C-terminal truncated proteins, the mRNAs generated by
CR-APA are not targeted by nonsense-mediated decay (Lejeune
and Maquat, 2005). For genes undergoing CR-APA, the efficiency
of polyadenylation contributes to gene expression through the
transcription termination efficiency. Additionally, the choice of
different poly(A) sites through APA determines both the mRNA
coding potential and 3′ UTR isoform. Dysfunctional polyadeny-
lation can lead to changes in the APA pattern, altering the protein
product and 3′ UTR, and to changes in polyadenylation efficiency,
both affecting gene expression.
CIS-ELEMENTS AND THE TRANS-ACTING POLYADENYLATION FACTORS
Cis-elements guiding polyadenylation
The cis-elements guiding polyadenylation of the nascent pre-
mRNA are positioned upstream or downstream relative to a
poly(A) site (Figure 2) (reviewed in Tian and Graber, 2012). The
poly(A) site is where the pre-mRNA molecule is cleaved, usually
immediately 3′ of a CA dinucleotide, and where the poly(A) tail on
the mature mRNA starts. Poly(A) sites normally contain two core
cis-elements: (1) The polyadenylation signal (PAS) placed 10–30nt
upstream of the poly(A) site, consisting of the canonical sequence
element, AAUAAA, found in more than half of mammalian genes,
or a weaker non-canonical variant (Beaudoing et al., 2000; Zhang
et al., 2005; Ho and Gunderson, 2011; Wang et al., 2013). (2) The
U/GU-rich downstream sequence element (DSE), located up to
30nt downstream of the poly(A) site. Additional elements such as
U-rich upstream sequence elements (USE), located just upstream
of the PAS (Moreira et al., 1998), G-rich auxiliary downstream
elements (Aux-DSE) (Chen and Wilusz, 1998), located down-
stream of the DSE, and UGUA motifs (Brown and Gilmartin, 2003;
Venkataraman et al., 2005; Yang et al., 2011) are found around
some poly(A) sites and all act as enhancers of polyadenylation.
The strength of a poly(A) site depends on the exact sequence of its
surrounding cis-elements, as well as their spatial placement, which
together determinates the affinity for the trans-acting factors. In
genes with only one poly(A) site, the PAS is typically canonical
(Beaudoing et al., 2000). In genes with multiple poly(A) sites, the
most distal poly(A) site generally has a canonical PAS whereas
the proximal poly(A) sites generally have a non-canonical PAS
(Beaudoing et al., 2000; Tian et al., 2005, 2007; Shepard et al.,
2011; de Klerk et al., 2012; Lin et al., 2012; Yoon et al., 2012;
Wang et al., 2013). The proximal poly(A) sites of skipped ter-
minal exons however tend to be associated with a canonical PAS
as well (Tian et al., 2007). Poly(A) sites with non-canonical cis-
elements are weaker and require additional factors for efficient
utilization (Fu et al., 2011), as seen for the weak proximal poly(A)
site in theCALCA gene encoding calcitonin/CGRP (Van Oers et al.,
1994; Lou et al., 1998). The distal poly(A) sites with canonical cis-
elements work as a secure last option for polyadenylation, ensuring
that transcription is terminated. This minimizes potentially dam-
aging read-through transcription into downstream genes, which
normally occurs for a small proportion of transcripts (Dresser
et al., 1995). The arrangement of the cis-elements with one A-
rich element associated with one or more U-rich elements around
the poly(A) site is generally conserved across eukaryotes (Millevoi
and Vagner, 2010). A comparison of orthologous human, rhe-
sus, dog, mouse, and rat genes, showed that poly(A) site usage
is strikingly similar in orthologous tissues between species (Tian
et al., 2005; Derti et al., 2012). The canonical PASs are position-
ally conserved between species (Derti et al., 2012), opposed to the
non-canonical PASs, which have been found to be less conserved
(Ara et al., 2006). Intronic poly(A) sites are also less conserved than
poly(A) sites in the 3′ UTR of terminal exons (Tian et al., 2007).
The non-canonical proximal poly(A) sites tend to have more con-
served flanking regions (Wang et al., 2008), in which conserved
motifs have been found, possibly explaining the relative frequent
usage of these poly(A) sites (Nunes et al., 2010; Ozsolak et al.,
2010).
Trans-acting polyadenylation factors (the human 3 ′-end processing
complex)
The human 3′-end processing complex consists of more than 80
proteins (Shi et al., 2009), which are highly conserved between
species (Darmon and Lutz, 2012). An important part of this com-
plex, the core polyadenylation machinery, consists of five multi-
subunit protein factors: cleavage and polyadenylation specificity
factor (CPSF), cleavage stimulation factor (CstF), cleavage fac-
tor I (CF-I), cleavage factor II (CF-II), and poly(A) polymerase
(PAP) (Table 1; Figure 2) (reviewed in Chan et al., 2011). The
endonucleolytic cleavage of the pre-mRNA is made by the CPSF-
73 subunit at the poly(A) site (Figure 2) (Mandel et al., 2006). The
pre-mRNA is typically cleaved immediately 3′ of a CA dinucleotide
(Danckwardt et al., 2008), although the exact cleavage site is usu-
ally clustered within a few nucleotides (Beaudoing et al., 2000;
Pauws et al., 2001; Tian et al., 2005; Lin et al., 2012). After cleavage
an untemplated poly(A) tail of about 250 adenosine-nucleotides
is added to the upstream cleavage product by PAP (Figure 2). This
is stimulated by the CPSF through the nuclear poly(A)-binding
protein (PABPN1), which binds the growing poly(A) tail and con-
trols its length (Kühn et al., 2009). Many of the other proteins in
the human 3′-end processing complex do not play a direct role in
the 3′-end formation, but instead couple polyadenylation to other
cellular processes.
REGULATION OF POLYADENYLATION
Polyadenylation is influenced by three factors: (1) The strength of
the cis-elements. (2) The concentration and activity of polyadeny-
lation factors. (3) The concentration and activity regulatory factors
(Barabino and Keller, 1999). These determine the efficiency of
polyadenylation and the pattern of APA. The regulation of consti-
tutive and alternative polydenylation differs and even CR-APA and
UTR-APA are regulated differently. This differentiated regulation
of APA is seen during T-cell activation, where CR-APA occurs at
both early and late stages of activation, utilizing both more prox-
imal and more distal poly(A) sites. In contrast, UTR-APA is most
evident in late stages of activation and dominantly utilize more
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FIGURE 2 | Cis-elements and polyadenylation factors. Light-green boxes
represent cis-elements in the pre-mRNA and light-purple boxes represent
polyadenylation factors. The endonucleolytic cleavage of the pre-mRNA is
made by the CPSF-subunit CPSF-73 at the poly(A) site, typically immediately
3′ of a CA dinucleotide. After cleavage, an untemplated poly(A) tail of about
250 adenosine-nucleotides, is added to the upstream cleavage product by
PAP. This is stimulated by the CPSF through the nuclear poly(A)-binding
protein (PABPN1) which binds the growing poly(A) tail and controls its length.
proximal poly(A) sites (Sandberg et al., 2008). The differentiated
regulation of APA is also seen during stem cell differentiation
where UTR-APA generally switches toward utilizing more distal
poly(A) sites, opposed to CR-APA which switches toward utilizing
both more proximal and more distal poly(A) sites (Shepard et al.,
2011). CR-APA often occurs together with alternative splicing of
the last exon and it is suggested that there is a dynamic competition
between splicing and polyadenylation (Tian et al., 2007; Evsyukova
et al., 2012). CR-APA is thus both regulated by polyadenylation and
splicing. The regulation of polyadenylation is complex and the
involved factors interact with several other cellular processes. Part
of the regulation is mediated through mechanistic interactions
with polyadenylation factors, enhancing, or inhibiting their func-
tion, competing for the binding to their cis-elements or reducing
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Table 1 |The core polyadenylation machinery.
Factor Subunits Necsessary for Interactions with
other core factors
Target cis-element Reference
CPSF CPSF-30, CPSF-73,
CPSF-100, CPSF-160,
hFip1, Wdr33, and
symplekin
Cleavage step and
polyadenylation step
CstF, CF-II, and PAP The PAS (AAUAAA), binding
mediated by CPSF-160
Murthy and Manley (1995),
Chan et al. (2011)
CstF CstF-50, CstF-64, and
CstF-77
Cleavage step CPSF and CF-II The DSE (U/GU-rich), binding
mediated by CstF-64
MacDonald et al. (1994), Chan
et al. (2011)
CF-I CF-I-25 and either
CF-I-68 or CF-I-59
Cleavage step CF-II and PAP The auxiliary motif UGUA Venkataraman et al. (2005),
Chan et al. (2011)
CF-II hPcf11 and hClp1 Cleavage step CPSF, CstF, and CF-I None Chan et al. (2011)
PAP None Cleavage step and
polyadenylation step
CPSF and CF-I None Chan et al. (2011)
their free levels in the nucleus (reviewed in Millevoi and Vagner,
2010).
Regulation by levels and variants of polyadenylation factors
It is hypothesized that higher levels of polyadenylation factors
lead to improved utilization of weaker proximal poly(A) sites,
encountered earlier during transcription (Figure 3). This is seen
during proliferation, where upregulated levels of polyadenylation
factors correlate with proximal poly(A) site usage (Elkon et al.,
2012). It is also seen for many of the individual core polyadenyla-
tion factors (see sections below). Every component, but not every
subunit, of the core polyadenylation machinery are regulated by
post-translational modifications, such as methylation, sumoyla-
tion, acetylation, and phosphorylation (reviewed in Ryan and
Bauer, 2008).
Cleavage and polyadenylation specificity factor. During col-
orectal carcinoma progression and in breast cancer cell lines,
upregulated levels of CPSF-subunits CPSF-73, CPSF-160, CPSF-
30, and symplekin correlate with proximal poly(A) site usage
(Mayr and Bartel, 2009; Morris et al., 2012). Interestingly, sym-
plekin is also highly overexpressed in colon, lung, muscle, and
prostate tumors where it promotes tumorigenesis (Buchert et al.,
2010). CPSF-160 and symplekin are expressed in high levels in
germ cells where the general 3′ UTR length is the shortest (Dass
et al., 2001; Liu et al., 2007). CPSF-100 was conversely down-
regulated. During the induction of stem cells from somatic cells,
all CPSF-subunits except CPSF-100 and hFip1, are upregulated.
This correlates with a general shift toward proximal poly(A) site
usage. During embryonic development all CPSF-subunits except
hFip1 are downregulated. This correlates with a general shift
toward distal poly(A) site usage (Ji and Tian, 2009; Ji et al., 2009).
The examples indicate that upregulated levels of CPSF enhance
polyadenylation, leading to proximal poly(A) site usage. Inter-
estingly, knockdown of the CPSF-subunit hFip1 increases DNA
damage and chromosome breakage (Stirling et al., 2012). This
is properly caused by dysfunctional polyadenylation, leading to
defective transcription termination, read-through transcription
and formation of R-loops (see section Sequence changes in genes
encoding polyadenylation factors, page 15).
Cleavage stimulation factor. Upregulated levels of the CstF sub-
unit CstF-64 correlate with proximal poly(A) site usage, during
colorectal carcinoma progression and in breast cancer cell lines
(Mayr and Bartel, 2009; Morris et al., 2012). Upregulated levels of
CstF-64 enhance utilization of proximal poly(A) sites in the mouse
Testis Brain RNA-Binding Protein (TB-RBP) gene in male germ
cells (Chennathukuzhi et al., 2001). CstF-64 is also upregulated in
activated immune cells, enhancing the usage of proximal poly(A)
sites (Shell et al., 2005; Sandberg et al., 2008). All CstF subunits are
upregulated, during the induction of stem cells from somatic cells,
correlating with a general shift toward proximal poly(A) site usage.
Additionally, these subunits are downregulated during embryonic
development, correlating with a general shift toward distal poly(A)
site usage (Ji and Tian, 2009; Ji et al., 2009). When comparing the
used poly(A) sites in genes that lengthen and genes that shorten
during the induction of stem cells from somatic cells, there was
major differences in the DSE. The DSE is where CstF binds, indi-
cating that CstF plays a crucial role in the regulation of poly(A)
site usage (Ji and Tian, 2009). The CstF-64 ortholog τCstF-64,
expressed at highest levels in testis and brain, is necessary for sper-
matogenesis and fertilization (Dass et al., 2007; Hockert et al.,
2011). Both CstF-64 and τCstF-64 are expressed in high levels in
germ cells, which have the shortest general 3′ UTR length (Dass
et al., 2001; Liu et al., 2007). Loss of τCstF-64 changes gene expres-
sion genome-wide in germ cells, leads to more frequent usage of
distal poly(A) sites and causes more read-through transcription
due to aberrant transcription termination (Li et al., 2012c). RNAi-
mediated depletion of CstF-64 has a small effect on APA, but leads
to upregulation of τCstF-64, suggesting that CstF-64 and τCstF-64
play redundant roles (Yao et al., 2012a). In support of this, during
differentiation of C2C12 myoblasts τCstF-64 is also upregulated
at the same time as the three subunits of CstF are downreulated
(Ji et al., 2009). Codepletion of CstF-64 and τCstF-64 leads to sig-
nificant changes in APA, with enhanced usage of distal poly(A)
sites (Yao et al., 2012a). Together this indicates that upregulation
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FIGURE 3 | APA under different cellular conditions. Green boxes
represent untranslated regions (UTRs), yellow boxes represent
exons, and the connecting horizontal lines represent introns.
Adapted from Di Giammartino et al. (2011). Blue poly(A) site
represents a proximal poly(A) site, which is normally non-canonical
and weaker. Red poly(A) site represents a distal poly(A) site, which
is normally canonical and stronger. Blue box: proliferation,
dedifferentiation and cell transformation upregulates the levels of
polyadenylation factors, enhancing the utilization of the weaker
proximal poly(A) site. Red box: differentiation downregulates the
levels of polyadenylation factors, leading to a utilization of the
stronger distal poly(A) site.
of CstF enhances polyadenylation, leading to the usage of proxi-
mal poly(A) sites. A CstF-64 splice variant βCstF-64 is expressed
specifically in nervous tissue and is thought to have regulatory
functions here (Shankarling et al., 2009). Interestingly, CstF-64
increases fivefold during cell cycle, at G0 to S phase transition
(Martincic et al., 1998) and low levels of CstF-64 cause reversible
cell cycle arrest while depletion causes apoptosis (Takagaki and
Manley, 1998).
Cleavage factor I. Cleavage factor I has been found to be impor-
tant for non-canonical poly(A) site usage by enhancing the recruit-
ment of CPSF (Brown and Gilmartin, 2003; Venkataraman et al.,
2005; Sartini et al., 2008; Yang et al., 2011). In the germ cells,
where the general 3′ UTR length is the shortest, the two CF-I
subunits CF-I-25 and CF-I-68 are upregulated (Liu et al., 2007;
Sartini et al., 2008). These two subunits are also upregulated dur-
ing the induction of stem cells from somatic cells, correlating with
a general shift toward proximal poly(A) site usage (Ji and Tian,
2009). These examples correlate well with the proposed function
of CF-I in promoting non-canonical poly(A) site usage. However,
reduced levels of CF-I has been found to enhance more proximal
poly(A) site usage (Kubo et al., 2006; Kim et al., 2010). Loss of
function of CF-I-25 and CF-I-68, but not of CF-I-59, have also
been found to enhance genome-wide proximal poly(A) site usage
(Gruber et al., 2012; Martin et al., 2012). This indicates that CF-I
has other functions than enhancing the recruitment of CPSF, yet
to be fully explained. Interestingly, downregulation of CF-I-68 has
also been found to increase tumor invasiveness (Yu et al., 2008).
Cleavage factor II. The CF-II subunit hClp1 is upregulated dur-
ing the induction of stem cells from somatic cells, correlating
with a general shift toward proximal poly(A) site usage (Ji and
Tian, 2009). Likewise, hClp1 is downregulated during embry-
onic development, correlating with a general shift toward distal
poly(A) site usage (Ji and Tian, 2009; Ji et al., 2009). In the germ
cells, where there is a short general 3′ UTR length, hClp1 is also
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upregulated (Liu et al., 2007). Low levels of the CF-II subunit
hPcf11 reduces transcription termination efficiency, due to weak-
ened polyadenylation (West and Proudfoot, 2008). Taken together
it shows that upregulation of CF-II enhances polyadenylation,
leading to proximal poly(A) site usage.
Poly(A) polymerase. In breast cancer cell lines, upregulated levels
of PAP correlate with proximal poly(A) site usage (Mayr and Bar-
tel, 2009). PAP is also upregulated during the induction of stem
cells from somatic cells, correlating with a general shift toward
proximal poly(A) site usage (Ji and Tian, 2009). These examples
indicate that upregulation of PAP enhances polyadenylation, lead-
ing to usage of proximal poly(A) sites. PAP is post-translationally
modified during cell cycle progression, with the modifications
reflecting the proliferative state of the cell (Thomadaki et al., 2008).
PAP modifications also correlate with apoptosis (Thomadaki et al.,
2008). One of the PAP regulators, poly(ADP-ribose) polymerase 1
(PARP1), modifies PAP during heat shock, leading to an inhibition
of polyadenylation (Di Giammartino et al., 2013). In addition to
PAP, three nuclear non-canonical PAPs exists: Neo-PAP, TRAP, and
Star-PAP. Neo-PAP has a function equal to that of PAP (Topalian
et al., 2001). TRAP is only expressed in testis and has functions
not fully understood (Lee et al., 2000). Star-PAP is necessary
for the 3′-end formation of selected mRNAs, such as the cyto-
protective enzyme heme oxygenase-1, which is upregulated in
response to oxidative stress (Mellman et al., 2008) and the BIK
protein, an initiator of mitochondrial apoptosis (Li et al., 2012b).
Star-PAP activity is modulated directly by phosphatidylinositol
4,5-bisphosphate (PI4,5P2) and Star-PAP associates with both
PIPKIα, which can generate new PI4,5P2, and with the PI4,5P2
sensitive protein kinase CKIα, which can phosphorylate Star-PAP
(Laishram et al., 2011). The phosphorylation of Star-PAP is critical
for its activity and PI4,5P2 sensitivity.
Other polyadenylation factors. The nuclear poly(A)-binding
protein (PABPN1) is upregulated during the induction of stem
cells from somatic cells, correlating with a general shift toward
proximal poly(A) site usage (Ji and Tian, 2009). However, PABPN1
recently has been shown to suppress polyadenylation at weaker
proximal poly(A) sites and loss of PABPN1 results in genome-
wide 3′ UTR shortening (de Klerk et al., 2012; Jenal et al., 2012).
Loss of PABPN1 also increases apoptotic markers in affected cells
(Bhattacharjee and Bag, 2012).
Regulation by non-polyadenylation factors
Splice factors. Many known splice factors have been shown to
affect polyadenylation (Table 2).
Non-splice factors. Many non-splice factors have also been shown
to affect polyadenylation (Table 3).
Regulation by transcription and co-transcriptional processes
Transcription. Polyadenylation is necessary for transcription ter-
mination (West and Proudfoot, 2009). It also affects transcription
re-initiation at upstream promoters (Mapendano et al., 2010). The
CTD of the Pol-II is necessary for the cleavage step in mammals
(Licatalosi et al., 2002). It recruits CPSF, CstF, and CF-II and trans-
fers them to their cis-elements in the pre-mRNA, as it emerges
from the Pol-II (McCracken et al., 1997; Lunde et al., 2010). The
recruitment is mediated by phosphorylation of the Pol-II CTD
serine 2 (Ser2) residues, which are progressively phosphorylated
during Pol-II elongation (Ahn et al., 2004). Poly(A) sites located
near the 5′-end of genes are normally not used, preventing pre-
mature 3′-end processing. This is probably because of the low
Ser2 phosphorylation in the Pol-II CTD right after transcription
initiation, resulting in inefficient recruitment of polyadenylation
factors (Guo et al., 2011). The general transcription factor TFIIB
is required for recruiting CPSF and CstF to the promoter (Wang
et al., 2010). The transcription elongation rate affects the choice
of poly(A) site, with a lower rate enhancing usage of proximal
poly(A) sites (Pinto et al., 2011). Transcription elongation fac-
tor ELL2 also enhances polyadenylation (Martincic et al., 2009).
Pol-II occupancy is found to be higher at distal poly(A) sites than
at proximal poly(A) sites (Lin et al., 2012). Transcriptional activ-
ity regulates APA, with highly expressed genes expressing short 3′
UTR isoforms and lowly expressed genes expressing long 3′ UTR
isoforms. This as the Pol-II is more likely to pause at poly(A)
sites in the highly expressed genes (Ji et al., 2011). As the mRNAs
with short 3′ UTRs generated from the highly expressed genes
are more stable and produce more protein, this effect potentiates
the gene expression difference. Transcriptional activators have also
been shown to enhance polyadenylation (Nagaike et al., 2011). The
choice of alternative 5′ UTRs and promoters affect the choice of
poly(A) site and thus APA (Winter et al., 2007; Ji et al., 2011).
Capping. The presence of a 5′-end m7GpppG cap has been shown
to positively affect the efficiency of polyadenylation (Cooke and
Alwine, 1996). The nuclear cap-binding complex (CBC), bound
to the 5′ cap, is necessary for assembling a stable 3′-end processing
complex. Depletion of CBC thus strongly reduces the efficiency of
the cleavage step (Flaherty et al., 1997).
Splicing. The patterns of APA and alternative splicing correlate
across tissues, indicating coordinated regulation of these processes
(Wang et al., 2008). Because the used intronic poly(A) sites are
usually located in large introns with weak 5′ splice sites, which
require more time to be spliced out, it has been suggested that
there is a dynamic competition between splicing and polyadeny-
lation (Tian et al., 2007; Evsyukova et al., 2012). Many of the
trans-factors involved in polyadenylation are also known to take
part in splicing (Shi et al., 2009; Evsyukova et al., 2012). Similarly,
a number of known splice factors have also been shown to affect
polyadenylation (Table 2).
Regulation by other processes
RNA structure. The secondary structure of RNA can affect
polyadenylation. This is seen in HIV-1-strains where the prox-
imal poly(A) site dominantly fold into a hairpin structure,
thereby inhibiting polyadenylation (Gee et al., 2006). Highly used
poly(A) sites are positively associated with an energetically favor-
able mRNA structure near poly(A) sites that exposes the PAS
(Khaladkar et al., 2011).
Nucleosome positioning. Decreased nucleosome density is found
around poly(A) sites, most significantly around the actively used
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Table 2 | Splice factors affecting polyadenylation.
Splice factor Motif Mechanism Effect on
polyadenylation
Reference
FOX-1/FOX-2
(neuronal-
specific)
UGCAUG Motifs are found in 3′ UTRs
between poly(A) sites, indicating a
role in APA regulation
Unknown Wang et al. (2008), Zhou et al.
(2007)
Nova (neuronal-
specific)
YCAY Enhances or inhibits polyadenylation
depending on the position of its
motif relative to the PAS
Enhance/inhibit Licatalosi et al. (2008)
U1 5′ splice site Represses adjacent downstream
intronic poly(A) site usage
Inhibit Kaida et al. (2010), Berg et al.
(2012), Vorlová et al. (2011),
Vickers et al. (2011)
Inhibits the PAP Inhibit Gunderson et al. (1998)
Intronic enhancer element
(with both 5’ and 3’ splice
sites)
Enhances upstream polyadenylation Enhance Lou et al. (1998)
U1A (component
of U1)
AUGCN(1-3)C Binds motifs downstream of poly(A)
site and inhibits CstF binding to the
DSE
Inhibit Phillips et al. (2004)
USE Enhances polyadenylation Enhance Hall-Pogar et al. (2007)
AUUGCAC Inhibits the PAP Inhibit Gunderson et al. (1997)
U2 3′ splice site Enhances adjacent downstream
poly(A) site usage
Enhance Kyburz et al. (2006)
U2 auxiliary factor
1 (U2AF1)
USE Enhances polyadenylation Enhance Danckwardt et al. (2007)
U2 auxiliary factor
2 (U2AF2)
3′ splice site Enhances adjacent downstream
poly(A) site usage
Enhance Millevoi et al. (2006)
Inhibits the PAP Inhibit Ko and Gunderson (2002)
hnRNP F DSE Competes with CstF for DSE
binding
Inhibit Veraldi et al. (2001)
hnRNP L CA-rich elements Inhibits the usage of intronic poly(A)
sites
Inhibit Hung et al. (2008)
hnRNP H Aux-DSE Enhances polyadenylaiton Enhance Dalziel et al. (2007)
hnRNP I (PTB) DSE Competes with CstF for DSE
binding
Inhibit Castelo-Branco et al. (2004)
USE Enhances polyadenylation Enhance Millevoi et al. (2009),
Hall-Pogar et al. (2007),
Blechingberg et al. (2007)
PTB associated
splicing factor
USE Enhances polyadenylation Enhance Hall-Pogar et al. (2007)
SR proteins Unknown Enhances polyadenylation Enhance Blechingberg et al. (2007)
SRp20 Intronic enhancer element
(with both 5’ and 3’ splice
sites)
Enhances upstream polyadenylation Enhance Lou et al. (1998)
SRp75 Unknown Inhibits the PAP Inhibit Ko and Gunderson (2002)
SRm160 Unknown Enhances polyadenylation Enhance McCracken et al. (2002, 2003)
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Table 3 | Non-splice factors affecting polyadenylation.
Factor Motif Mechanism Effect on polyadenylation Reference
E2F TTGGCGG Motifs are enriched in promoter-regions of many
polyadenylation factors and E2F enhances their
expression
Upregulation of
polyadenylation factors
leading to 3′ UTR shortening
Elkon et al. (2012), Ji
and Tian (2009)
Hu proteins U-rich
sequences
Inhibits CstF binding to the DSE at poly(A) sites
containing U-rich sequences
Inhibit Zhu et al. (2007)
NS1 (Influenza
A virus protein)
None Interacts with CPSF-30 and inhibits polyadenylation of
host pre-mRNAs in infected cells
Inhibit Nemeroff et al. (1998)
14-3-3ε None Inhibits the PAP and redistributes it to the cytoplasm Inhibit Kim et al. (2003)
CSR1 None Redistributes CPSF-73 to the cytoplasm Inhibit Zhu et al. (2009)
IRBIT None In response to oxidative stress, IRBIT is
phosphorylated, whereby it both inhibits PAP and
redistributes the CPSF-subunit hFip1 to the cytoplasm
Inhibit Kiefer et al. (2009)
p53 None In response to DNA damage, p53 complexes with
BARD1 and CstF-50, lowering the free levels of
CstF-50
Inhibit Nazeer et al. (2011)
BRCA1 None In response to DNA damage, BRCA1 complexes with
BARD1 and CstF-50, lowering the free levels of
CstF-50
Inhibit Kleiman and Manley
(2001)
Cdc73 None Associates with CPSF-CstF complexes and stimulates
polyadenylation of specific target genes
Enhance Rozenblatt-Rosen et al.
(2009)
HSF1 None In response to cellular stress, HSF1 complexes with
symplekin and CstF-64 and enhances polyadenylation
of Hsp70
Enhance Xing et al. (2004)
P54 USE Enhances polyadenylation Enhance Hall-Pogar et al. (2007)
p38 MAPK None In response to cellular stess, p38 MAPK
phosphorylates RBPs blocking the USE, leading to
their dissociation, and upregulates several
polyadenylation factors, both events leading to
enhanced polyadenylation
Enhance Danckwardt et al. (2011)
T3 None T3 stimulates the nuclear polyadenylaiton step,
mediated by PAP, increasing poly(A) tail length of
P450R
Enhance Liu and Waxman (2002)
FSH None Stimulates proximal poly(A) site usage in CREM gene Enhance Foulkes et al. (1993)
Estrogen None Induces 3′ UTR shortening of the DNA replication
regulator CDC6
Enhance Akman et al. (2012)
ones (Spies et al., 2009). Increased nucleosome density is found
downstream of poly(A) sites, most significantly downstream of
the actively used ones (Spies et al., 2009; Khaladkar et al., 2011).
Highly expressed genes have a lower nucleosome density around
poly(A) sites than genes expressed at low levels (Ji et al., 2011).
Epigenetic modifications. Allele-specific poly(A) site usage is
seen in an imprinted mouse gene (H13), as a result of DNA-
methylation. A CpG island separates polyA sites utilized in H13.
Alleles without methylation of the CpG island utilize a proximal
poly(A) site, generating a truncated H13, whereas alleles with
methylation of the CpG island, utilize downstream poly(A) sites
(Wood et al., 2008). Histone methylation (H3K36me3) decreases
downstream of used poly(A) sites (Lian et al., 2008; Wang
et al., 2013). Highly expressed genes have increased levels of
histone methylation (H3K4me3 and H3K36me3) around prox-
imal poly(A) sites compared to around distal poly(A) sites (Ji
et al., 2011; Lin et al., 2012). The pattern of histone modifica-
tions can thus characterize poly(A) sites and even discriminate
between poly(A) sites with high and low usage, suggesting a link
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between chromatin structure and mRNA structure (Khaladkar
et al., 2011).
Circadian rhythms. The suppressor of cytokine signaling 3
(SOCS3) mRNA, encodes a protein important for the leptin sig-
naling pathway. SOCS3 mRNA is expressed in two isoforms due
to APA. The two isoforms are expressed in an oscillating pattern
and in opposite phases (Ptitsyn and Gimble, 2007).
METHODS FOR CHARACTERIZING POLY(A) SITE USAGE
COMPLEMENTARY DNAs, EXPRESSED SEQUENCE TAGS, AND
MICROARRAYS
Early studies to identify poly(A) sites in human were done by
aligning complementary DNAs (cDNAs) and expressed sequence
tags (ESTs) to the genome, thereby identifying the 3′ end of genes.
These analyses revealed that more than half of human genes have
multiple poly(A) sites and undergo APA (Beaudoing et al., 2000;
Tian et al., 2005; Yan and Marr, 2005). Later studies using microar-
ray platforms were designed to characterize APA in different cell
types, cancers, and at different development stages. These analyses
showed that a general 3′ UTR shortening associates with increased
proliferation, dedifferentiation, and cell transformation (Sandberg
et al., 2008; Ji and Tian, 2009; Singh et al., 2009) whereas a gen-
eral 3′ UTR lengthening associates with cell differentiation (Ji and
Tian, 2009; Ji et al., 2009). Poly(A) site usage were also found to
differ according to tissue type, developmental stage, genotype, and
cancer subtype (Kwan et al., 2008; Sandberg et al., 2008; Ji and
Tian, 2009; Ji et al., 2009; Singh et al., 2009). The cDNA and EST
methods have limited statistical power and microarrays are lim-
ited to comparing the results only with already known poly(A)
sites and have difficulties with quantifying the different 3′-UTR
isoforms produced by APA. Thus new methods for characterizing
poly(A) site usage were needed.
HIGH-THROUGHPUT SEQUENCING TECHNIQUES
With the development of new high-throughput sequencing tech-
niques, several methods have been developed to specifically char-
acterize poly(A) site usage genome-wide (Mangone et al., 2010;
Ozsolak et al., 2010; Fox-Walsh et al., 2011; Fu et al., 2011; Jan
et al., 2011; Shepard et al., 2011; Derti et al., 2012; Jenal et al.,
2012; Lin et al., 2012; Martin et al., 2012; Pelechano et al., 2012;
Yoon et al., 2012; Hoque et al., 2013; Wang et al., 2013; Wilken-
ing et al., 2013). These new techniques provide higher coverage
than any of the previous methods, allow better detection of the
poly(A) sites and give a more precise quantification of their rel-
ative usage. High-throughput sequencing studies have confirmed
that more than half of human genes have multiple poly(A) sites
and undergo APA (Derti et al., 2012). They have also confirmed
that 3′ UTR shortening associates with proliferation (Elkon et al.,
2012) and that 3′ UTR lengthening associates with differentia-
tion (Shepard et al., 2011). However, they have not unanimously
confirmed that 3′ UTR shortening associates with cell transforma-
tion, but instead found that APA patterns can shift for both more
proximal and more distal poly(A) site usage during cell transfor-
mation (Fu et al., 2011; Elkon et al., 2012; Lin et al., 2012; Morris
et al., 2012). Several computational studies have been performed
to characterize patterns in the cis-elements around used poly(A)
sites obtained from experiments (Beaudoing et al., 2000; Legendre
and Gautheret, 2003; Tian et al., 2005; Ara et al., 2006; Nunes
et al., 2010; Ozsolak et al., 2010). Computational methods have
also been developed to identify poly(A) sites (Tabaska and Zhang,
1999; Graber et al., 2002; Hajarnavis et al., 2004; Bajic et al., 2005;
Cheng et al., 2006; Retelska et al., 2006; Akhtar et al., 2010).
THE POLYADENYLATION PATTERN
CHANGED PATTERNS OF POLYADENYLATION UNDER DIFFERENT
CELLULAR CONDITIONS
Changes in cellular conditions can cause a widespread dynamic
shift in the use of poly(A) sites by APA, altering the 3′ UTRs, and in
some cases the coding potential of the mRNAs. A shift toward more
proximal poly(A) site usage associates with increased proliferation
(Sandberg et al., 2008; Elkon et al., 2012) and with dedifferenti-
ation (Ji and Tian, 2009). In contrast, shift toward more distal
poly(A) site usage associates with cell differentiation (Figure 3)
(Ji and Tian, 2009; Ji et al., 2009; Mangone et al., 2010; Hilgers
et al., 2011; Shepard et al., 2011). The developmental potency of
a cell seems to be inversely correlated to 3′ UTR length, with the
3′ UTR being shortest in germ cells< stem cells< partly differ-
entiated cells< terminally differentiated cells (Figure 4) (Ji and
Tian, 2009; Shepard et al., 2011). 3′ UTR shortening has also
been reported to be associated with cell transformation (Mayr
and Bartel, 2009; Singh et al., 2009; Lin et al., 2012; Morris et al.,
2012). Recent studies have however found that this association
is inconsistent (Fu et al., 2011; Elkon et al., 2012). Interestingly,
there is an enrichment of binding sites for several transcription
factors involved in proliferation/differentiation, including E2F, c-
myc, and p53 in the promoter-regions of many of the genes coding
for polyadenylation factors (Ji and Tian, 2009; Elkon et al., 2012).
High levels of E2F have been shown to enhance the expression of
polyadenylation factors. E2F transcription factors are upregulated
during proliferation (Elkon et al., 2012). This might explain the
shift in the APA during proliferation, while changes in levels of
other transcription factors might explain the shift in APA during
differentiation. Activation of neurons also induce 3′ UTR short-
ening for multiple genes (Flavell et al., 2008). This is due to the
relative shortage of splice factor U1 generated by the transcrip-
tional upregulation found in activated neurons, as shortage of U1
leads to enhanced usage of proximal poly(A) sites (Berg et al.,
2012).
During cell differentiation/dedifferentiation
Generally the 3′ UTRs shorten when inducing pluripotent stem
cells from somatic cell types, the opposite of what happens during
embryonic development. When inducing from germ cells 3′ UTRs
generally lengthen, the opposite of what happens during postnatal
testis development (Ji and Tian, 2009). The genes with 3′ UTR
shortening during the induction were more likely to have had
3′ UTR lengthening during embryonic development. Vice versa,
the genes with 3′ UTR lengthening during the induction were
more likely to have had 3′ UTR shortening during embryonic
development (Ji and Tian, 2009). The proximal poly(A) sites
highly responsive to cell state change during the induction of
somatic cells, were also highly regulated during embryonic devel-
opment, but in the opposite direction. When comparing these
www.frontiersin.org May 2013 | Volume 4 | Article 53 | 11
Rehfeld et al. Altered polyadenylation in endocrine disease
FIGURE 4 | 3′ UTR length and developmental potential. The developmental potency of a cell seems to be inversely correlated to 3′ UTR length. The 3′ UTR is
shortest in germ cells< stem cells<partly differentiated cells< terminally differentiated cells, due to different APA patterns in these cells.
poly(A) sites with less responsive proximal poly(A) sites in other
genes, they were more conserved, had stronger DSE and lead to
longer alternative 3′ UTRs (Ji and Tian, 2009). A recent high-
throughput sequencing study also found a correlation between 3′
UTR lengthening and differentiation (Shepard et al., 2011).
During proliferation and cell transformation
A general shift toward more proximal poly(A) site usage is seen
during increased proliferation, leading to 3′ UTR shortening.
Enhanced usage of proximal intronic poly(A) sites is also seen,
leading to changes in mRNA CRs (Sandberg et al., 2008; Elkon
et al., 2012). 3′ UTR shortening has also been reported be asso-
ciated to cell transformation (Mayr and Bartel, 2009; Singh et al.,
2009; Morris et al., 2012), with the transformed cells expressing
mRNAs with shorter 3′ UTRs compared with non-transformed
cells with similar proliferation rate (Mayr and Bartel, 2009). 3′
UTR shortening has also been associated with poor cancer prog-
nosis (Lembo et al., 2012). 3′ UTR shortening is, e.g., seen for
fibroblast growth factor 2 (FGF-2), which is involved in tumor
neovascularization. The distal poly(A) site is primarily utilized in
fibroblasts, in contrast to in transformed cell lines, where more
proximal poly(A) sites are utilized (Touriol et al., 1999). The 3′
UTR shortening is stronger during the transition from arrested to
proliferative state than during the transition from proliferative to
transformed state (Elkon et al., 2012). Recent studies have found
the association between 3′ UTR shortening and cell transforma-
tion to be inconsistent. One study found an even distribution
between genes with 3′ UTR shortening and lengthening in one
transformed cell line (Elkon et al., 2012). Another study found a
shift toward usage of more distal poly(A) sites for the majority
of genes in another transformed cell line (Fu et al., 2011). Both
these studies did however find a general 3′ UTR shortening in
Frontiers in Endocrinology | Genomic Endocrinology May 2013 | Volume 4 | Article 53 | 12
Rehfeld et al. Altered polyadenylation in endocrine disease
other transformed cell lines (Fu et al., 2011; Elkon et al., 2012).
Yet other studies found a general 3′ UTR shortening compared to
matched normal tissue, both in tumor samples from five differ-
ent tissues (Lin et al., 2012) and in several colorectal carcinomas
(Morris et al., 2012). These examples illustrate that the shifts in
poly(A) site usage in transformed cells is more complex than just
a shift toward usage of more proximal poly(A) sites.
THE POLYADENYLATION PATTERN AS A BIOMARKER
Poly(A) site usage differs according to tissue type, developmental
stage, genotype, and cancer subtype (Breton et al., 2001; Zhang
et al., 2005; Kubo et al., 2006; Kwan et al., 2008; Sandberg et al.,
2008; Wang et al., 2008; Ji and Tian, 2009; Ji et al., 2009; Singh
et al., 2009; Thomsen et al., 2010; Derti et al., 2012; MacIsaac
et al., 2012). This makes the polyadenylation pattern a candidate
biomarker, which could be used for, e.g., cancer classification.
Tissue-specific APA is common and often associated with the
proximal non-canonical poly(A) sites (Beaudoing et al., 2000).
It has been estimated that 52% of all CR-APA events and 80%
of all UTR-APA events are regulated differentially between tis-
sues (Wang et al., 2008), making tissue-specific UTR-APA events
even more differentially regulated than tissue-specific alternative
splicing.
ALTERATIONS IN POLYADENYLATION IN ENDOCRINE
DISEASE
SEQUENCE CHANGES IN AND AROUND CIS-ELEMENTS
Changes in the sequence in and around cis-elements can disrupt
normal polyadenylation and cause disease (reviewed in Danck-
wardt et al., 2008). Single nucleotide polymorphisms (SNPs) have
been identified that can both create or disturb PASs (Thomas
and Sætrom, 2012). SNPs in PASs can affect mRNA length and
expression, and are significant predictors of gene expression lev-
els (Thomas and Sætrom, 2012; Yoon et al., 2012). SNPs can also
affect APA. A significant high fraction of the SNPs which affect
APA, are linked to SNPs found by genome-wide association stud-
ies (GWAS). A high proportion of the APA-alleles created by these
SNPs, are positively correlated with disease-risk alleles (Thomas
and Sætrom, 2012). GWAS-indentified trait-associated SNPs are
generally overrepresented in the 3′ UTRs of genes, possibly cre-
ating, or affecting the cis-elements involved in polyadenylation
(Arnold et al., 2012).
Loss of function changes
A functional poly(A) site is required for polyadenylation and thus
transcription termination (Connelly and Manley, 1988; West and
Proudfoot, 2009). Loss of function changes in the cis-elements
of poly(A) sites, can therefore lead to reduced gene expression
caused by weakened polyadenylation efficiency. Such loss of func-
tion changes are associated with various diseases. They were first
described in the PAS of the only poly(A) site in the HBA2 gene
causing α-thalassemias (Higgs et al., 1983; Harteveld et al., 1994)
and in a PAS in the HBB gene causing β-thalassemias (Orkin
et al., 1985; Jankovic et al., 1990; Rund et al., 1992; van Solinge
et al., 1996). Loss of function changes causing disease, frequently
seem to affect the PAS, which in one of the two core cis-elements
found at poly(A) sites. Any possible base change in the canoni-
cal PAS (AAUAAA) significantly reduce polyadenylation efficiency
(Sheets et al., 1990). The PAS is responsible for binding the core
polyadenylation factor CPSF, which is required for polyadenyla-
tion (Chan et al., 2011). The reduced efficiency of polyadenylation
associated with changes to the canonical PAS, is thus caused by
weakened recruitment of CPSF to poly(A) sites. The examples
of endocrine diseases affected by loss of function changes in and
around cis-elements of poly(A) sites are described below.
Neonatal diabetes. A loss of function mutation in the INS gene
PAS has been shown to cause neonatal diabetes. This disruptive
mutation changes the PAS of the only poly(A) site (AAUAAA
to AAUAAG), reducing insulin mRNA expression to less than
3× 10-4 percent (Garin et al., 2010). The authors hypothesize
that this is due to impaired mRNA stability. However, such a low
expression level is more likely a result of weakened polyadenyla-
tion efficiency of the only poly(A) site in the INS gene, leading to
impaired transcription termination and thus reduced gene expres-
sion, as seen similarly for other genes (Higgs et al., 1983; Bennett
et al., 2001; Stacey et al., 2011). The change of the PAS sequence
(AAUAAA to AAUAAG) reduces polyadenylation efficiency about
98% (Sheets et al., 1990). As the PAS is crucial for binding CPSF,
the reduced polyadenylation efficiency in the mutated INS gene is
due to weakened CPSF recruitment (Chan et al., 2011).
Immune dysfunction, polyendocrinopathy, enteropathy, X-
linked. A loss of function mutation in the PAS of the only
poly(A) site in the FOXP3 gene causes immune dysfunction,
polyendocrinopathy, enteropathy, X-linked (IPEX). The mutation
changes the PAS (AAUAAA to AAUGAA), leading to diminished
FOXP3 mRNA expression (Bennett et al., 2001). This is probably
due to impaired polyadenylation of the only poly(A) site in the
FOXP3 gene, leading to non-termination of transcription, as seen
similarly for other genes (Higgs et al., 1983; Stacey et al., 2011).
The change of the PAS sequence (AAUAAA to AAUGAA) reduces
polyadenylation efficiency about 95% (Sheets et al., 1990). The
PAS is vital for binding CPSF, hence the impaired polyadenylation
of the mutated FOXP3 gene is due to weakened binding of CPSF
(Chan et al., 2011).
Mayer–Rokitanski–Küster–Hauser syndrome. The AMH gene
encoding Anti-Müllerian Hormone is located only 739 bp down-
stream of the housekeeping gene encoding splicing factor 3a sub-
unit 2 (SF3a2) (Dresser et al., 1995), a component of the splice
factor U2 (Bennett and Reed, 1993). Read-through transcription
of the SF3a2 gene into the AMH gene, due to failed polyadenyla-
tion of the SF3a2 gene, is normally seen for a small proportion of
transcripts (Dresser et al., 1995). This leads to constitutive expres-
sion of AMH along with SF3a2 and results in higher than normal
AMH levels. It is hypothesized, that polymorphisms around the
SF3a2 gene poly(A) site leading to reduced polyadenylation with
more read-through transcription, could cause Mayer–Rokitanski–
Küster–Hauser (MRKH) syndrome. MRKH syndrome is charac-
terized by the Müllerian ducts failing to develop into the uterus,
cervix, and upper vagina. Polymorphisms around the SF3a2 gene
poly(A) site were however not found in 30 MRKH patients
examined in one study (Oppelt et al., 2005).
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Hypothalamic-pituitary-adrenal axis dysregulation. In the
serotonin transporter (SERT ) gene a PAS U/G polymorphism
exists in the distal, more canonical poly(A) site. The G-allele
changes the PAS (AUUAAC to AGUAAC) leading to a lesser usage
of the distal poly(A) site. This reduces total SERT expression to
about half in the brain (Gyawali et al., 2010). This is sensible as
the distal, canonical poly(A) site is most efficient for polyadenyla-
tion and most frequently utilized, therefore yielding higher mRNA
expression levels (Wang et al., 2013). The G-allele is associated
with an increased risk for panic disorder (Gyawali et al., 2010),
as well as heightened anxiety and depressive symptoms (Hart-
ley et al., 2012). Interestingly, the SSRI fluoxetine increases the
usage of the distal poly(A) site, suggesting that the therapeutic
effect of this compound depends on alterations in polyadenyla-
tion (Hartley et al., 2012). Serotonin has many functions in the
endocrine system, e.g., in the regulation of the hypothalamic-
pituitary-adrenal axis (Heisler et al., 2007). This suggests that the
SERT gene polymorphism could have endocrine implications as
well.
Cancer. In the PAS of the only poly(A) site in the TP53 gene a
A/C polymorphism exists. The C-allele changes the PAS (AAUAAA
to AAUACA), leading to impaired polyadenylation and transcrip-
tion termination. This results in decreased p53 mRNA expression
and read-through trancription. The change of the PAS sequence
(AAUAAA to AAUACA) reduces polyadenylation efficiency about
89% (Sheets et al., 1990). CPSF binds the PAS, so the reduced
polyadenylation efficiency is due to weakened binding of CPSF
(Chan et al., 2011). The C-allele is associated with various cancer
diseases (Stacey et al., 2011; Zhou et al., 2012). This polymorphism
could be important for endocrine tumor diseases as well, as loss
of p53 is an important event in the pathogenesis of many tumors,
e.g., thyroid tumors (Yoshimoto et al., 1992).
Gain of function changes
Gain of function changes in the cis-elements of poly(A) sites, can
lead to enhanced gene expression caused by improved polyadeny-
lation efficiency and to changes in APA. Such gain of function
changes are associated with various diseases. They were first
described in the CA dinucleotide immediately 5′ of the cleav-
age site in the F2 gene encoding thrombin (Gehring et al., 2001;
Ceelie et al., 2004; Danckwardt et al., 2004, 2006, 2007). Later they
were also described in the DSE of the F2 gene (Danckwardt et al.,
2004), as well as in the DSE of the FGG gene encoding fibrino-
gen gamma (Lisman et al., 2005; Uitte de Willige et al., 2007).
All of these mutations cause thrombophilia through enhanced
polyadenylation efficiency, leading to upregulated gene expression.
The examples of endocrine diseases affected by gain of function
changes in and around cis-elements of poly(A) sites are described
below.
Type I diabetes. The GIMAP5 gene has two poly(A) sites in its
3′ UTR. In the PAS of the proximal poly(A) site a G/A polymor-
phism exists. The minor A-allele changes the PAS to a canoni-
cal one (AAUAGA to AAUAAA) leading to enhanced proximal
poly(a) site usage (Shin et al., 2007). The change of the PAS
sequence (AAUAGA to AAUAAA) increases polyadenylation effi-
ciency about 25-fold (Sheets et al., 1990). The A-allele is associated
with high levels of tyrosine phosphatase (IA-2) autoantibodies,
which are reported to be associated with clinical onset of type I
diabetes (Shin et al., 2007). Interestingly, the G-allele is associ-
ated with an increased risk of systemic lupus erythematosus (SLE)
(Hellquist et al., 2007). The A-allele induce a higher proportion
of mRNAs with the short 3′ UTR isoform, but was not found to
have an effect on total GIMAP5 mRNA levels (Hellquist et al.,
2007). Differences in translational efficiency between the mRNAs
with the long and short 3′ UTR isoforms are thus believed to be
affecting the levels of IA-2 autoantibodies.
Type II diabetes. A proximal intronic poly(A) site in the tran-
scription factor 7-like 2 (TCF7L2) gene has been found. Usage of
this poly(A) site leads to production of a C-terminally truncated
protein isoform that repress T-cell factor/lymphoid-enhancer fac-
tor (TCF/LEF)-dependent target genes (Locke et al., 2011). The
authors hypothesize that this poly(A) site might explain why
intronic SNPs in theTCF7L2 gene are associated with a risk of type
2 diabetes, as they could enhance the utilization of this poly(A) site.
IGF-1 deficiency. A U/A polymorphism in a proximal poly(A)
site PAS of the insulin-like growth factor 1 (IGF-1) gene 3′ UTR
has been described. It changes the PAS (AAUAUA to AAAAUA),
leading to expression of a shorter than normal IGF-1 mRNA. The
U/A polymorphism has been reported in a child born small for
gestation age with IGF-1 deficiency (Bonapace et al., 2003). A later
study however reported that this polymorphism along with other
polymorphisms in this PAS of the IGF-1 gene do not cause IGF-1
deficiency nor growth impairment (Coutinho et al., 2007).
Endocrine tumor diseases. A C/T polymorphism in the RET
proto-oncogene, six nucleotides upstream of an intronic proxi-
mal poly(A) site PAS of intron 19 exists (Gartner et al., 2005).
The adjacent poly(A) site is commonly used for polyadenylation
by CR-APA. The C/T polymorphism lies within a binding site of
the nucleic acid binding protein Pbx1 (AAATTAG(C/T)T), which
might affect polyadenylation at the adjacent poly (A) site. The T-
allele carriers have the more canonical binding motif for Pbx1.
Heterozygosity for the T-allele was found in a significantly higher
number of patients with various endocrine tumors than in healthy
controls. Homozygosity for the T-allele was exclusively found in
DNA from endocrine tumors with a high malignant potential, as
a result of loss of heterozygosity (LOH) in these tumors (Gartner
et al., 2005). This suggests that Pbx1 enhances polyadenylation at
the adjacent poly(A) site, leading to higher expression levels of
RET.
Cancer. Gain of function mutations have been found in the
CCND1 gene encoding Cyclin D1 in mantle cell lymphoma (MCL)
tumors. These mutations create new proximal poly(A) sites, giv-
ing rise to expression of truncated mRNAs lacking most of the 3′
UTR. These truncated mRNAs are associated with strongly prolif-
erative MCL tumors and inferior survival (Wiestner et al., 2007).
Such mutations could be important for endocrine tumor diseases
as well, as high expression of Cyclin D1 is associated with many
cancers, e.g., pancreatic endocrine tumors (Guo et al., 2003).
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SEQUENCE CHANGES IN GENES ENCODING POLYADENYLATION
FACTORS
Cancer
Mutations in yeast polydadenylation factors have been shown to
disrupt normal transcription termination (Birse et al., 1998) and
to cause inefficient transcription elongation (Luna et al., 2005).
They have also been shown to cause genome instability, through
formation of R-loops (Stirling et al., 2012). R-loops are persistent,
transcription-associated RNA:DNA hybrids that expose damage-
prone single stranded DNA (ssDNA) on the nonsense strand and
may block the replication fork progression (Stirling et al., 2012).
Non-terminated pre-mRNA transcripts, which form due to defec-
tive cleavage at the poly(A) site (Birse et al., 1998), could form the
basis of these RNA:DNA hybrids found in R-loops. Genome insta-
bility is found in many human cancers, in part due to increased
chromosome instability (CIN), which is linked to R-loops (Wahba
et al., 2011). CIN is normally found as an early event in the
oncogenic process and can lead to loss or gain of whole chro-
mosomes or chromosomal fragments. Researchers working with
yeast strains, each with mutations in one gene out of 305 genes
involved with CIN, found that mutations in 44 of the genes
resulted in an indicated increased CIN. Seven of these 44 genes
encoded subunits of polyadenylation factors. They were homologs
of CPSF-subunits CPSF-100, hFip1, and Wdr33, CstF subunit
CstF-64, both subunits of CF-II and yeast factor HRP1, lacking
a human homolog. The mutant stains had indicated increased
CIN in all cell cycle stages (Stirling et al., 2012). Genome-wide
analysis of fragile chromatin sites in these mutant stains sup-
ported a transcription-dependent mechanism of DNA damage,
characteristic of R-loop formation. Increased RNA:DNA hybrid
formation in polyadenylation factor mutant stains were found and
the resulting CIN could be suppressed by RNaseH, which degrades
the RNA and thereby removes the R-loops (Stirling et al., 2012).
The researchers found that small interfering RNA (siRNA) knock-
down of the CPSF-subunit hFip1 in human cells increased DNA
damage and chromosome breakage (Stirling et al., 2012). Interest-
ingly, hFip1 also comprises the N-terminal part of a fusion protein
with platelet-derived growth factor receptor alpha (PDGFRα),
which causes 14–60% the incidents of hypereosinophilic syn-
drome/chronic eosinophilic leukemia (Cools et al., 2003; Gotlib
and Cools, 2008; Li et al., 2012a). Truncation fusions of yeast
FIP1, analogous to those found for hFip1 in chronic eosinophilic
leukemia, was found to cause genome instability in yeast (Stir-
ling et al., 2012). All these findings indicate that the normal 3′-end
processing complex maintains genome integrity by suppressing R-
loop formation, thereby suppressing CIN, a function that may be
impaired in many human cancers (Stirling et al., 2012). Mutations
in genes encoding polyadenylation factors could be important for
endocrine tumor diseases, as CIN is already known as a power-
ful prognostic indicator for endocrine pancreatic tumor patients
(Jonkers et al., 2007).
SEQUENCE CHANGES IN GENES ENCODING REGULATORY FACTORS
Hereditary and sporadic parathyroid tumors
The tumor suppressor protein Cdc73 is mutationally inac-
tivated in hereditary and sporadic parathyroid tumors
(Rozenblatt-Rosen et al., 2009). It normally associates with
CPSF-CstF complexes and enhances polyadenylation of specific
target genes. The inactivation of Cdc73 leads to decreased associ-
ation of CPSF-CstF complexes with these target genes, reducing
their expression levels (Rozenblatt-Rosen et al., 2009). This sug-
gests that impaired polyadenylation of these target genes plays a
part in the parathyroid tumorigenesis.
OTHER MECHANISMS LEADING TO ALTERATIONS IN
POLYADENYLATION
Fragile X-associated premature ovarian insufficiency
A shift in poly(A) site usage due to UTR-APA is seen in the fragile
X mental retardation 1 (FMR1) gene premutation alleles com-
pared to normal alleles (Tassone et al., 2011). The FMR1 gene 5′
UTR contains a CGG repeat element that is expanded to more
than 200 CGG repeats and methylated in fragile X syndrome.
The premutation alleles of the FMR1 gene, with 55–200 CGG
repeats, are associated with various phenotypes, including fragile
X-associated premature ovarian insufficiency (Toniolo and Rizzo-
lio, 2007). These phenotypic manifestations could be a result of
the UTR-APA of the FMR1 pre-mRNA. The choice of alternative
5′ UTRs affects the choice of poly(A) site (Winter et al., 2007; Ji
et al., 2011). This could explain how the CGG expansion in the 5′
UTR of the FMR1 gene affects the choice of poly(A) site by altering
the transcription start site (Tassone et al., 2011).
Diabetic nephropathy
A high-glucose-regulated gene, HGRG-14, found in human
mesangial cells, is expressing a longer isoform of HGRG-14 mRNA
due to UTR-APA under high-glucose conditions (Abdel Wahab
et al., 1998). This results in lower HGRG-14 protein levels. The
switch from the shorter to the longer isoform is detected within
2 h of exposure to high-glucose levels and the authors hypoth-
esize that this may be involved in the pathogenesis of diabetic
nephropathy (Abdel Wahab et al., 1998).
Medullary thyroid carcinoma
Human Thyroid C cells express an alternative isoform of calci-
tonin mRNA, containing all exons of the CALCA gene, producing
calcitonin, and calcitonin carboxyl terminal peptide II (CCP II).
Expression of this isoform is seen in low levels in normal subjects.
In medullary thyroid carcinomas expression is more abundant,
leading to higher plasma levels of CCP II (Minvielle et al., 1991).
CCP II could thus be used as a diagnostic marker for medullary
thyroid carcinomas. As the alternative processing of the CALCA
gene occurs through APA, polyadenylation regulation may be
aberrant in the medullary thyroid carcinomas.
Pre-eclampsia
Soluble fms-like tyrosine kinase 1 (sFlt-1) arises from CR-APA
utilizing an intronic poly(A) site in the FLT1 gene encoding VEGF
receptor 1 (Thomas et al., 2007). sFlt-1 binds VEGF and thereby
reduces its free circulating level. Expression of sFlt-1 is upreg-
ulated in cytotrophoblasts during hypoxia and is suggested to
induce endothelial damage (Nagamatsu et al., 2004; Zhao et al.,
2012). sFlt-1 expression is increased in pre-eclampsia and evidence
suggests that it causes the development of the disease (Shibata
et al., 2005; Zhao et al., 2012). Selective expression of sFlt-1
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can be induced by targeting the 5′ splice site with an antisense
oligonucleotide, thereby inhibiting U1 binding (Vorlová et al.,
2011). This hints that U1 plays a role in the upregulation of
sFlt-1. Several techniques using antisense elements can inhibit
poly(A) site usage (see section Treatment by altering polyadeny-
lation) (Beckley et al., 2001; Fortes et al., 2003; Goraczniak et al.,
2009; Vickers et al., 2011; Vorlová et al., 2011; Blazquez et al., 2012;
Vickers and Crooke, 2012). These techniques could be used to
lower the expression of sFlt-1, possibly alleviating the symptoms
or even treating pre-eclampsia in the future. Interestingly, sFlt-1 is
also increased in type II diabetes (Nandy et al., 2010).
Ectopic Cushing syndrome
Ectopic Cushing syndrome is cause by adrenocorticotropic hor-
mone (ACTH) production in non-pituitary tumors, such as small
cell lung cancers, which is normally non-suppressible (Parks et al.,
1998). An ACTH-producing small cell lung cancer was shown to
express a C-terminally truncated isoform of glucocorticoid recep-
tor due to CR-APA using an intronic poly(A) site. This caused the
ACTH production to be non-suppressible by exogenous glucocor-
ticoid administration (Parks et al., 1998). Several techniques using
antisense elements can inhibit poly(A) site usage (see Treatment by
altering polyadenylation) (Beckley et al., 2001; Fortes et al., 2003;
Goraczniak et al., 2009; Vickers et al., 2011; Vorlová et al., 2011;
Blazquez et al.,2012;Vickers and Crooke,2012). If these techniques
were used to target the intronic poly(A) site utilized by CR-APA,
the normal full length isoform of glucocorticoid receptor would be
expressed. This would render the ACTH production suppressible
by glucocorticoids, possibly treating the Cushing syndrome.
Adrenal and gonadal dysfunction
The gene encoding the steroidogenic acute regulatory (StAR) pro-
tein express two mRNA isoforms (1.6 and 3.5 kb) differing only
in the length of their 3′ UTR due to UTR-APA (Duan et al.,
2009). StAR regulates the rate-limiting step in steroid biosyn-
thesis. ACTH stimulates the StAR function by increasing cAMP
and cAMP-protein kinase A (PKA) activity, leading to prefer-
ential expression of the longer, less stable 3.5 kb StAR mRNA
isoform (Zhao et al., 2005). PKA also stimulate transcription of
the RBP TIS11b, which selectively binds the 3.5 kb mRNA iso-
form and destabilizes it, while at the same time enhancing StAR
protein translation (Duan et al., 2009). Aberrant expression of
StAR due to alterations in polydenylation could cause abnormal
steroid production and adrenal/gonadal dysfunction, as seen for
other disruptive mutations leading to enhanced or diminished
StAR expression (Okuhara et al., 2008; Sahakitrungruang et al.,
2010).
TREATMENT BY ALTERING POLYADENYLATION
ANTISENSE ELEMENTS TARGETING SPECIFIC POLY(A) SITES
Enhancing poly(A) site usage
Specific usage of selected intronic poly(A) sites can be induced
by targeting the upstream 5′ splice site with an antisense oligonu-
cleotide, thereby inhibiting U1 binding (Vorlová et al., 2011). As
U1 associating with 5′ splice sites represses adjacent downstream
intronic poly(A) site, this enhances the usage of these intronic
poly(A) sites and leads to expression of C-terminal truncated pro-
teins (Kaida et al., 2010; Vorlová et al., 2011; Berg et al., 2012).
Unlike mRNAs with acquired premature termination codons,
which also generate C-terminal truncated proteins, the mRNAs
generated by usage of intronic poly(A) sites are not targeted by
nonsense-mediated decay (Lejeune and Maquat, 2005). Thou-
sands of dormant intronic poly(A) sites have been characterized
(Yao et al., 2012a). Induced usage of any of these sites can lead to
the expression of specific C-terminal truncated protein isoforms.
Inhibiting poly(A) site usage
Different techniques using antisense elements have been used
to effectively inhibit poly(A) site usage. They include antisense
oligonucleotides (Vorlová et al., 2011), siRNAs (Vickers and
Crooke, 2012), and U1 modifications (Beckley et al., 2001; Fortes
et al., 2003; Goraczniak et al., 2009; Vickers et al., 2011; Blazquez
et al., 2012). The techniques can both induce APA and lead to sig-
nificantly reduced gene expression, depending on the poly(A) site
targeted.
DRUGS TARGETING POLYADENYLATION FACTORS
The specific PAP inhibitor cordycepin is an adenosine-nucleotide
analog. It reduces polyadenylation efficiency and causes defects in
transcription termination (Kondrashov et al., 2012). Cordycepin
has been shown to inhibit proliferation and induce apoptosis in
various cancer cell lines (Thomadaki et al., 2008; Imesch et al.,
2011). Cordycepin also inhibit the induction of inflammatory
genes mediated by cytokines (Kondrashov et al., 2012).
PERSPECTIVES
Recently, the field of polyadenylation has seen major progress.
Advances in high-throughput sequencing have made it possible
to characterize polyadenylation genome-wide and lowered the
price to ∼100$ per sample (Wang et al., 2013). This has stimu-
lated the field and more research on polyadenylation is now being
published. This will help to find more endocrine pathways regu-
lated by polyadenylation and thus to discover novel implications
of alterations in polyadenylation for endocrine disease. The low-
ered cost of genome-wide characterization of polyadenylation will
also push forward the implementation of this technique into the
clinic to improve diagnostics. For instance, cancers show charac-
teristic changes in APA patterns (Mayr and Bartel, 2009; Singh
et al., 2009; Fu et al., 2011; Elkon et al., 2012; Lin et al., 2012; Mor-
ris et al., 2012). The inclusion of APA screenings in diagnostics
could therefore help to produce more accurate diagnoses by, e.g.,
differentiating between cancer subtypes. It is therefore crucial to
increase the awareness about the importance of polyadenylation
among physicians and scientists working with endocrinology.
Alternative polyadenylation is increasingly being recognized as
an important regulator of the human transcriptome, like alter-
native splicing. It has been estimated that 52% of all CR-APA
events and 80% of all UTR-APA events are regulated differen-
tially between tissues,making tissue-specific UTR-APA events even
more differentially regulated than tissue-specific alternative splic-
ing (Wang et al., 2008). Interestingly, changes in the APA pattern
is seen during changes in cellular conditions, such as prolifera-
tion, differentiation, cellular transformation, and dedifferentiation
(Sandberg et al., 2008; Ji and Tian, 2009; Mayr and Bartel, 2009;
Singh et al., 2009; Fu et al., 2011; Elkon et al., 2012; Lin et al., 2012;
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Morris et al., 2012). Unlike mRNAs created by alternative splicing,
mRNAs generated by CR-APA are not targeted by nonsense-
mediated decay, thus lead to the production of C-terminally trun-
cated protein isoforms (Lejeune and Maquat, 2005). Such isoforms
can have significantly altered functions (Vorlová et al., 2011) and
have been suggested to cause diseases such as pre-ecclamsia (Zhao
et al., 2012). C-terminally truncated protein isoforms generated
by CR-APA could be causative of many other diseases. UTR-APA
alters the 3′ UTR length and induces changes in stability and trans-
lational efficiency for individual mRNAs (Sandberg et al., 2008;
Mayr and Bartel, 2009; Singh et al., 2009; Hogg and Goff, 2010;
Yepiskoposyan et al., 2011). However, the effect of global changes
in 3′ UTR length remains mysterious as no significant change in
mRNA levels were seen in several cases with general changes in
3′ UTR length (Sandberg et al., 2008; Fu et al., 2011; Elkon et al.,
2012; Morris et al., 2012). The latter findings could be explained
by the mRNAs competing for trans-acting factors. For instance,
in activated neurons, a general upregulation of pre-mRNAs, leads
to a relative shortage of splice factor U1, which in turn, leads to
changes in APA (Berg et al., 2012). Similarly, a general change in
mRNA 3′ UTR length could lead to a relative shortage/abundance
of trans-acting factors, giving rise to a relative weaker effect on
gene expression levels, than seen for a single gene expressing an
alternative 3′ UTR isoform. It would however still be interesting
to investigate the changes in protein translation efficiency in cells
with general changes in 3′ UTR length.
Both loss of function and gain of function changes in and
around poly(A) sites have been shown to cause disease (reviewed
in Danckwardt et al., 2008). It is probable that loss of function
changes most frequently cause disease, when affecting the stronger,
more canonical poly(A) site of a gene. Firstly, these sites are most
efficient for polyadenylation and the most commonly utilized.
Usage of these sites therefore give rise to higher mRNA expression
levels (Wang et al., 2013). Secondly, these sites are often found
as the most distal poly(A) site, which works as the last option
for polyadenylation and ensures that transcription is terminated
(Beaudoing et al., 2000; Tian et al., 2005, 2007; Shepard et al.,
2011; de Klerk et al., 2012; Lin et al., 2012; Yoon et al., 2012; Wang
et al., 2013). When loss of function changes affect these more
canonical poly(A) sites, the effect on gene expression is therefore
strong. This is seen for the SERT gene encoding a SERT. Here a
loss of function change in the PAS of the distal, canonical poly(A)
site, changes the PAS (AUUAAC to AGUAAC). This leads to lesser
usage of the poly(A) site, reducing total SERT expression to about
half (Gyawali et al., 2010). When loss of function changes affect
the poly(A) site in genes where only one poly(A) site is found,
the effect on gene expression is even stronger, as no alternative
poly (A) sites may be used. This is seen for the INS, FOXP3, and
TP53 genes, where loss of function changes in the PAS of the only
poly(A) site in these genes, lead to an almost diminished gene
expression (Bennett et al., 2001; Garin et al., 2010; Stacey et al.,
2011). When loss of function changes affect the weaker poly(A)
sites in genes with multiple poly(A) sites, the effect is changes in
the APA pattern, altering the 3′ UTR and in some cases the pro-
tein product. Gene expression is also affected, but often in a more
subtle way. Interestingly, loss of function changes causing disease
also commonly seem to affect the PAS (Higgs et al., 1983; Bennett
et al., 2001; Garin et al., 2010; Gyawali et al., 2010; Stacey et al.,
2011). This is predictable, as the PAS is one of the two core cis-
elements found at poly(A) sites. It is essential for binding CPSF,
which is required for both the cleavage and the polyadenylation
step (Chan et al., 2011). It is important to note that loss of func-
tion changes can also lead to subclinical manifestations, as seen in
the metachromatic leukodystrophy pseudodeficiency phenotype.
Here a change in the PAS (AAUAAC to AGUAAC) of a majorly
used proximal poly(A) site in the ARSA gene reduces gene expres-
sion by 90%(Gieselmann et al., 1989). Conversely, it seems that
gain of function changes associated with disease often affect prox-
imal poly(A) sites. This is expected, as the proximal poly(A) sites
are generally weaker and therefore have the biggest potential to be
enhanced (Beaudoing et al., 2000; Tian et al., 2005, 2007; Shepard
et al., 2011; de Klerk et al., 2012; Lin et al., 2012; Yoon et al., 2012;
Wang et al., 2013). Interestingly, gain of function changes causing
disease also commonly seem to affect other cis-elements than the
PAS, as seen for the CA dinucleotide immediately 5′ of the cleav-
age site and for the DSE (Gehring et al., 2001; Ceelie et al., 2004;
Danckwardt et al., 2004, 2006, 2007; Uitte de Willige et al., 2007).
This is also anticipated, as improvement of auxiliary cis-elements
can both enhance polyadenylation at poly(A) sites with a canonical
PAS and at poly(A) sites with a non-canonical PAS.
Various techniques using specific antisense elements that
enhance or inhibit the usage of specific poly(A) sites exists (Beck-
ley et al., 2001; Fortes et al., 2003; Goraczniak et al., 2009; Vickers
et al., 2011; Vorlová et al., 2011; Blazquez et al., 2012; Vickers
and Crooke, 2012). These techniques hold great promises of novel
therapeutic approaches, as they can both induce APA and change
gene expression significantly. One obvious use would be to reverse
the effect of disease-causing mutations affecting polyadenylation.
However, they could also be used to treat diseases,where alterations
in polyadenylation do not take part in the pathogenesis. One way of
treating could be by inducing the expression of C-terminally trun-
cated protein isoforms. This primarily leads to loss of function of
the full length product, but the expressed C-terminally truncated
protein isoforms can have beneficial functions on their own. This
is seen for the VEGF receptor, where a C-terminally truncated
isoform functions as a soluble decoy. Induction of this isoform
resulted in an antiangiogenic effect both in targeted cells and in
untreated cells exposed to the conditioned media (Vorlová et al.,
2011). Another way to treat using these techniques, is by signifi-
cantly reducing gene expression by inhibiting the more canonical
poly(A) site (Goraczniak et al., 2009; Blazquez et al., 2012). A
potential side-effect free usage of these techniques, would be to
inhibit premature intronic poly(A) sites, which are used in dis-
eased cells, but not in healthy cells. As polyadenylation is inhibited
at the intronic poly(A) site, the targeted intron will be spliced out
and degraded, leaving the healthy cells unaffected by the treatment.
In conclusion, the clinical implications of the current state of
research in this field are: (1) Poly(A) site usage differs according
to tissue type, developmental stage, genotype, and cancer subtype
(Breton et al., 2001; Zhang et al., 2005; Kubo et al., 2006; Kwan
et al., 2008; Sandberg et al., 2008; Wang et al., 2008; Ji and Tian,
2009; Ji et al., 2009; Singh et al., 2009; Thomsen et al., 2010; Derti
et al., 2012; MacIsaac et al., 2012). Characterization of polyadeny-
lation can therefore improve diagnostics and poly(A) site usage
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would be a candidate diagnostic biomarker for, e.g., cancer classi-
fication. (2) Many diseases and symptoms are caused by defective
polyadenylation (reviewed in Danckwardt et al., 2008). Several
endocrine diseases are either caused by or associated with alter-
ations in polyadenylation. These are neonatal diabetes (Garin et al.,
2010), IPEX (Bennett et al., 2001), type I and II diabetes (Shin et al.,
2007; Locke et al., 2011), pre-eclampsia (Zhao et al., 2012), frag-
ile X-associated premature ovarian insufficiency (Tassone et al.,
2011), ectopic Cushing syndrome (Parks et al., 1998), and several
types of endocrine tumor diseases (Minvielle et al., 1991; Gartner
et al., 2005). Consequently, the advances in this field therefore lead
to a better understanding of these diseases and expose new pos-
sible drug targets. (3) Novel techniques using antisense elements
that can both enhance and inhibit the usage of specific poly(A)
sites have been developed (Beckley et al., 2001; Fortes et al., 2003;
Goraczniak et al., 2009; Vickers et al., 2011; Vorlová et al., 2011;
Blazquez et al., 2012; Vickers and Crooke, 2012). These techniques
hold the promise of novel therapeutic approaches, through desired
induced changes in polyadenylation.
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